Web Exclusives

Web Exclusives published on November 13, 2018 in FDA Approvals, News & Updates
In August, the FDA approved lenvatinib for the first-line treatment of patients with unresectable hepatocellular carcinoma, based on the results of the REFLECT clinical trial.
Web Exclusives published on November 13, 2018 in Immunotherapy
“This study is a fantastic advance for patients with brain metastases. It shows that combination immunotherapy can shrink brain metastases in a substantial proportion of patients,” said Michael A. Postow, MD.
Web Exclusives published on October 22, 2018 in Immunotherapy
“The overall survival findings are far superior to what we might anticipate with traditional therapies in this relapsed or refractory DLBCL population,” said Jeremy S. Abramson, MD, MMSc.
Web Exclusives published on October 22, 2018 in Breast Cancer
Analysis of a phase 3 clinical trial showed that 6 months of trastuzumab was noninferior to 12 months in terms of disease-free survival, and was also associated with a 50% reduction in cardiotoxicity.
Web Exclusives published on October 16, 2018 in Immunotherapy
At ASCO 2018, 3 new studies that explore chemotherapy plus immunotherapy got high remarks from Sibylle Loibl, MD, PhD, including a regimen that may be a new standard of care.
Web Exclusives published on October 16, 2018 in Lynch Syndrome
The novel drug sacituzumab govitecan is showing significant promise in HER2-negative breast cancers. “The benefit was durable, with an estimated medical duration of response of 7.4 months,” reported Aditya Bardia, MD, MPH.
Web Exclusives published on October 15, 2018 in Breast Cancer

The novel drug sacituzumab govitecan is showing significant promise in HER2-negative breast cancers. “The benefit was durable, with an estimated medical duration of response of 7.4 months,” reported Aditya Bardia, MD, MPH.

Web Exclusives published on October 9, 2018 in Immunotherapy, Multiple Myeloma

The second-generation chimeric antigen receptor (CAR) T-cell therapy, bb2121, engineered to target B-cell maturation antigen, a protein on the surface of certain myeloma cells, displayed continuing efficacy and safety in an update of a phase 1 clinical trial in patients with relapsed or refractory multiple myeloma.

Web Exclusives published on September 7, 2018 in Emerging Therapies
“Both responders and those who didn’t respond to ivosidenib achieved transfusion independence. Ivosidenib was well-tolerated, and adverse events were managed with standard of care,” said Daniel A. Pollyea, MD, MS, at ASCO 2018.
Web Exclusives published on September 4, 2018 in Health Policy
FDA Commissioner Scott Gottlieb, MD, announced new steps as part of the FDA’s Drug Competition Action Plan to promote generic drug competition as a way to expand potential access to inexpensive medicines, which would be especially helpful for patients with cancer.
Page 3 of 11
Results 21 - 30 of 109